Evaxion A/S American Depositary Share
EVAX
Closed
$3.15
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Key stats
Open
$3.19
Volume
22.06K
Market cap
$27.11M
Prev. close
$3.20
Impl / hst vl
-
Open interest
$0.00
$3.12
Day’s Range
$3.19
$2.87
52W Range
$5.48
Valuation
11
Valuation score
Strongly Overvalued
P/E
-
P/S
-
P/B
1.59
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
-
Income growth
-38.68%
FCF growth
-
Analysts estimates
Consensus rating
Buy
The average rating from top 7 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$11.48
The top 6 analysts forecasts that 12-month price may increase by 264.29%, with a low of $9.09 and a high of $16.80
$9.09
Low
$11.48
Avg
$16.80
High
Current price
Earnings
Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$3.63M
Revenue
Net income
Previous EPS
-$0.50
Estimate EPS
-$0.32
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply